DiaSorin Receives CE Mark for Simplexa Group B Strep Assay | 360Dx

DiaSorin Receives CE Mark for Simplexa Group B Strep Assay

Oct 18, 2018

This article has been updated from a previous version to correct the technology used in the Meridian H. Pylori assay.

NEW YORK (GenomeWeb) – DiaSorin Molecular said today that it has received CE marking for its Simplexa Group B Strep Direct assay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

The BD Veritor Plus System

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Mar

28

Featured Webinar

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.

Apr

11

Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr

17

Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.